Association of type o blood with pancreatic neuroendocrine tumors in von Hippel-Lindau syndrome

Allison B. Weisbrod, David J. Liewehr, Seth M. Steinberg, Erin E. Patterson, Steven K. Libutti, W. Marston Linehan, Naris Nilubol, Electron Kebebew

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background. ABO blood type antigens are expressed not only on human red blood cells, but also throughout the gastrointestinal tract and in normal pancreatic tissue. Previous studies have identified an association between ABO blood type and various malignancies. We analyzed the association of ABO blood type with pancreatic neuroendocrine tumors (PNETs) in a high-risk cohort of patients with Von Hippel-Lindau (VHL) syndrome. Methods. A retrospective review was performed of 798 patients with VHL syndrome. Blood type was confirmed for 181 patients. Fisher's exact test and Mehta's modification to Fisher's exact test were used to test for an association between ABO blood type and manifestations of VHL syndrome. Results. We found a strong trend for association between O blood type and pancreatic disease manifestation in patients with VHL syndrome (P = 0.047). More importantly, there was a significant association of O blood type with solid pancreatic lesions consistent with PNETs (P = 0.0084). Patients with solid pancreatic lesions who met criteria for surgical resection at the National Institutes of Health also had a higher rate of O blood type than those who did not require surgery (P = 0.051). Conclusions. Our findings suggest an association between O blood type and pancreatic manifestation of disease in patients with VHL syndrome, especially for PNETs. Screening and surveillance approaches for pancreatic lesions in patients with VHL syndrome should also consider patient blood type. The possibility of A, B, H misexpression in PNETs should also be explored to determine whether the serologic association with disease translates into a relationship with tissue pathology.

Original languageEnglish (US)
Pages (from-to)2054-2059
Number of pages6
JournalAnnals of Surgical Oncology
Volume19
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

von Hippel-Lindau Disease
Neuroendocrine Tumors
Pancreatic Diseases
Hematologic Diseases
National Institutes of Health (U.S.)
Gastrointestinal Tract
Erythrocytes
Pathology
Antigens

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Weisbrod, A. B., Liewehr, D. J., Steinberg, S. M., Patterson, E. E., Libutti, S. K., Linehan, W. M., ... Kebebew, E. (2012). Association of type o blood with pancreatic neuroendocrine tumors in von Hippel-Lindau syndrome. Annals of Surgical Oncology, 19(6), 2054-2059. https://doi.org/10.1245/s10434-012-2276-8

Association of type o blood with pancreatic neuroendocrine tumors in von Hippel-Lindau syndrome. / Weisbrod, Allison B.; Liewehr, David J.; Steinberg, Seth M.; Patterson, Erin E.; Libutti, Steven K.; Linehan, W. Marston; Nilubol, Naris; Kebebew, Electron.

In: Annals of Surgical Oncology, Vol. 19, No. 6, 06.2012, p. 2054-2059.

Research output: Contribution to journalArticle

Weisbrod, AB, Liewehr, DJ, Steinberg, SM, Patterson, EE, Libutti, SK, Linehan, WM, Nilubol, N & Kebebew, E 2012, 'Association of type o blood with pancreatic neuroendocrine tumors in von Hippel-Lindau syndrome', Annals of Surgical Oncology, vol. 19, no. 6, pp. 2054-2059. https://doi.org/10.1245/s10434-012-2276-8
Weisbrod AB, Liewehr DJ, Steinberg SM, Patterson EE, Libutti SK, Linehan WM et al. Association of type o blood with pancreatic neuroendocrine tumors in von Hippel-Lindau syndrome. Annals of Surgical Oncology. 2012 Jun;19(6):2054-2059. https://doi.org/10.1245/s10434-012-2276-8
Weisbrod, Allison B. ; Liewehr, David J. ; Steinberg, Seth M. ; Patterson, Erin E. ; Libutti, Steven K. ; Linehan, W. Marston ; Nilubol, Naris ; Kebebew, Electron. / Association of type o blood with pancreatic neuroendocrine tumors in von Hippel-Lindau syndrome. In: Annals of Surgical Oncology. 2012 ; Vol. 19, No. 6. pp. 2054-2059.
@article{bc027dd45cfb4d838f7d1e64c7cbafde,
title = "Association of type o blood with pancreatic neuroendocrine tumors in von Hippel-Lindau syndrome",
abstract = "Background. ABO blood type antigens are expressed not only on human red blood cells, but also throughout the gastrointestinal tract and in normal pancreatic tissue. Previous studies have identified an association between ABO blood type and various malignancies. We analyzed the association of ABO blood type with pancreatic neuroendocrine tumors (PNETs) in a high-risk cohort of patients with Von Hippel-Lindau (VHL) syndrome. Methods. A retrospective review was performed of 798 patients with VHL syndrome. Blood type was confirmed for 181 patients. Fisher's exact test and Mehta's modification to Fisher's exact test were used to test for an association between ABO blood type and manifestations of VHL syndrome. Results. We found a strong trend for association between O blood type and pancreatic disease manifestation in patients with VHL syndrome (P = 0.047). More importantly, there was a significant association of O blood type with solid pancreatic lesions consistent with PNETs (P = 0.0084). Patients with solid pancreatic lesions who met criteria for surgical resection at the National Institutes of Health also had a higher rate of O blood type than those who did not require surgery (P = 0.051). Conclusions. Our findings suggest an association between O blood type and pancreatic manifestation of disease in patients with VHL syndrome, especially for PNETs. Screening and surveillance approaches for pancreatic lesions in patients with VHL syndrome should also consider patient blood type. The possibility of A, B, H misexpression in PNETs should also be explored to determine whether the serologic association with disease translates into a relationship with tissue pathology.",
author = "Weisbrod, {Allison B.} and Liewehr, {David J.} and Steinberg, {Seth M.} and Patterson, {Erin E.} and Libutti, {Steven K.} and Linehan, {W. Marston} and Naris Nilubol and Electron Kebebew",
year = "2012",
month = "6",
doi = "10.1245/s10434-012-2276-8",
language = "English (US)",
volume = "19",
pages = "2054--2059",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Association of type o blood with pancreatic neuroendocrine tumors in von Hippel-Lindau syndrome

AU - Weisbrod, Allison B.

AU - Liewehr, David J.

AU - Steinberg, Seth M.

AU - Patterson, Erin E.

AU - Libutti, Steven K.

AU - Linehan, W. Marston

AU - Nilubol, Naris

AU - Kebebew, Electron

PY - 2012/6

Y1 - 2012/6

N2 - Background. ABO blood type antigens are expressed not only on human red blood cells, but also throughout the gastrointestinal tract and in normal pancreatic tissue. Previous studies have identified an association between ABO blood type and various malignancies. We analyzed the association of ABO blood type with pancreatic neuroendocrine tumors (PNETs) in a high-risk cohort of patients with Von Hippel-Lindau (VHL) syndrome. Methods. A retrospective review was performed of 798 patients with VHL syndrome. Blood type was confirmed for 181 patients. Fisher's exact test and Mehta's modification to Fisher's exact test were used to test for an association between ABO blood type and manifestations of VHL syndrome. Results. We found a strong trend for association between O blood type and pancreatic disease manifestation in patients with VHL syndrome (P = 0.047). More importantly, there was a significant association of O blood type with solid pancreatic lesions consistent with PNETs (P = 0.0084). Patients with solid pancreatic lesions who met criteria for surgical resection at the National Institutes of Health also had a higher rate of O blood type than those who did not require surgery (P = 0.051). Conclusions. Our findings suggest an association between O blood type and pancreatic manifestation of disease in patients with VHL syndrome, especially for PNETs. Screening and surveillance approaches for pancreatic lesions in patients with VHL syndrome should also consider patient blood type. The possibility of A, B, H misexpression in PNETs should also be explored to determine whether the serologic association with disease translates into a relationship with tissue pathology.

AB - Background. ABO blood type antigens are expressed not only on human red blood cells, but also throughout the gastrointestinal tract and in normal pancreatic tissue. Previous studies have identified an association between ABO blood type and various malignancies. We analyzed the association of ABO blood type with pancreatic neuroendocrine tumors (PNETs) in a high-risk cohort of patients with Von Hippel-Lindau (VHL) syndrome. Methods. A retrospective review was performed of 798 patients with VHL syndrome. Blood type was confirmed for 181 patients. Fisher's exact test and Mehta's modification to Fisher's exact test were used to test for an association between ABO blood type and manifestations of VHL syndrome. Results. We found a strong trend for association between O blood type and pancreatic disease manifestation in patients with VHL syndrome (P = 0.047). More importantly, there was a significant association of O blood type with solid pancreatic lesions consistent with PNETs (P = 0.0084). Patients with solid pancreatic lesions who met criteria for surgical resection at the National Institutes of Health also had a higher rate of O blood type than those who did not require surgery (P = 0.051). Conclusions. Our findings suggest an association between O blood type and pancreatic manifestation of disease in patients with VHL syndrome, especially for PNETs. Screening and surveillance approaches for pancreatic lesions in patients with VHL syndrome should also consider patient blood type. The possibility of A, B, H misexpression in PNETs should also be explored to determine whether the serologic association with disease translates into a relationship with tissue pathology.

UR - http://www.scopus.com/inward/record.url?scp=84865113591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865113591&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2276-8

DO - 10.1245/s10434-012-2276-8

M3 - Article

C2 - 22350603

AN - SCOPUS:84865113591

VL - 19

SP - 2054

EP - 2059

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -